Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Jul;78(7):954-63.
doi: 10.1002/jmv.20647.

Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant

Takeshi Ichinohe  1 , Izumi Watanabe, Eriko Tao, Satoshi Ito, Akira Kawaguchi, Shin-ichi Tamura, Hidehiro Takahashi, Hirofumi Sawa, Masami Moriyama, Joe Chiba, Katsuhiro Komase, Yujiro Suzuki, Takeshi Kurata, Tetsutaro Sata, Hideki Hasegawa
Affiliations

Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant

Takeshi Ichinohe et al. J Med Virol. 2006 Jul.

Abstract

A safe and effective adjuvant is necessary to enhance mucosal immune responses for the development of an inactivated intranasal influenza vaccine. The present study demonstrated the effectiveness of surf clam microparticles (SMP) derived from natural surf clams as an adjuvant for an intranasal influenza vaccine. The adjuvant effect of SMP was examined when co-administered intranasally with inactivated A/PR8 (H1N1) influenza virus hemagglutinin vaccine in BALB/c mice. Administration of the vaccine with SMP induced a high anti-PR8 haemagglutinin (HA)-specific immunoglobulin A (IgA) response in the nasal wash and immunoglobulin G (IgG) response in the serum, resulting in protection against both nasal-restricted infection and lethal lung infection by A/PR8 virus. In addition, administration of SMP with A/Yamagata (H1N1), A/Beijing (H1N1), or A/Guizhou (H3N2) vaccine conferred complete protection against A/PR8 virus challenge in the nasal infection model, suggesting that SMP adjuvanted vaccine can confer cross-protection against variant influenza viruses. The use of SMP is suggested as a new safe and effective mucosal adjuvant for nasal vaccination against influenza virus infection.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types

MeSH terms

Substances

LinkOut - more resources